1. Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B et al (2005) Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23:17–23
2. Albain K, Barlow W, O’Malley F, Siziopikou K, Yeh IT, Ravdin P et al (2004) Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium, San Antonio, Texas
3. American Cancer Society (2005) Cancer facts and figures, available online under www.cancer.org/docroot/STT/stt_0.asp
4. Arcangeli G, Pinnaro P, Rambone R, Giannarelli D, Benassi M (2005) A Phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys, in press
5. ATAC Trialists Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62